| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate |
2003-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2006-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006505500-A |
| titleOfInvention |
In-vivo effective broad spectrum superantigen toxin antagonist based on the interaction of CD28 with superantigen and use thereof |
| abstract |
The present invention relates to a superantigen binding site within the CD28 molecule comprising part or all of the amino acid sequence HVKGKHLCP (also shown in SEQ ID NO: 3). This site binds specifically and directly to the superantigen through the spatially conserved domain of pyrogenic exotoxin, which is not involved in binding to either MHC class II molecules or TCRs. . Direct binding of the CD28 molecule to the superantigen at this site promotes the binding of the B7-2 ligand to CD28 and is defined in Th1 lymphocytes as defined by induction of IL-2 and / or IFN-g gene expression. Indispensable for activation. The present invention provides substances that inhibit superantigen-mediated activation of Th1 lymphocytes by inhibiting this interaction, thereby protecting against toxic shock and also inducing protective immunity. . The invention further comprises a CD28 molecule or s-Ag binding site thereof in a method for screening for a test substance that specifically binds to CD28 molecule and can antagonize pyrogenic exotoxin-mediated activation of Th1 lymphocytes. Regarding the use of fragments. |
| priorityDate |
2002-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |